A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers
Phase 1 Terminated
22 enrolled
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Phase 1 Terminated
17 enrolled
Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies
Phase 1/2 Terminated
58 enrolled 11 charts
Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides
Phase 1/2 Terminated
5 enrolled
BDI
Phase NA Terminated
1 enrolled
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Phase 1 Terminated
249 enrolled 43 charts
PARCT
Phase 2 Terminated
26 enrolled
Ipilimumab and Local Radiation for Selected Solid Tumors
Phase 1 Terminated
3 enrolled 5 charts
REACH
Phase 2 Terminated
2 enrolled
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
Phase 2 Terminated
20 enrolled 8 charts
CTCL
Phase 2 Terminated
2 enrolled 7 charts
Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma
Phase 2 Terminated
16 enrolled 16 charts
Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL
Phase 3 Terminated
59 enrolled
Part B
Phase 1 Terminated
2 enrolled
SOLAR
Phase 2 Terminated
37 enrolled 23 charts
Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas
Phase 4 Terminated
100 enrolled
A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma
Phase 2 Terminated
16 enrolled
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
Phase 1/2 Terminated
20 enrolled 17 charts
Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL)
Phase 2 Terminated
9 enrolled 6 charts
CTCL
Phase 2 Terminated
1 enrolled
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies
Phase 1 Terminated
2 enrolled 6 charts
Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders
Phase 1 Terminated
4 enrolled
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
Phase 1 Terminated
5 enrolled
PRISM
Phase 2 Terminated
8 enrolled
Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer
Phase NA Terminated
1 enrolled 3 charts
Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma
Phase 1 Terminated
8 enrolled
Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphoma
Phase 1 Terminated
6 enrolled
Mindfulness Interventions and Cutaneous T Cell Lymphoma (CTCL)
Phase NA Terminated
3 enrolled
T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
Terminated
150 enrolled
Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma
Phase 1 Terminated
7 enrolled 11 charts
Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary Syndrome
Phase 1 Terminated
14 enrolled 7 charts
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
Phase 2 Terminated
1 enrolled 4 charts
Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma
Phase NA Terminated
25 enrolled 15 charts
A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma
Phase 1/2 Terminated
32 enrolled 12 charts
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Phase 2 Terminated
4 enrolled 4 charts
Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma
Phase 1 Terminated
3 enrolled
RFT5-dgA Immunotoxin in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma
Phase 2 Terminated
1 enrolled 1 chart
Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL
Phase NA Terminated
7 enrolled 5 charts
Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma
Phase 2 Terminated
11 enrolled 11 charts
Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial
Terminated
241 enrolled
STAT3 in T Cells: At The Crossroads of Inflammation and Cancer
Terminated
35 enrolled
Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer
Terminated
1,000 enrolled
Lenalidomide Maintenance Post-debulking in Advanced CTCL
Phase 3 Terminated
21 enrolled
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Phase NA Terminated
43 enrolled
Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides
Phase 1/2 Terminated
28 enrolled 13 charts
Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant
Phase 2 Terminated
3 enrolled 10 charts
Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase NA Terminated
1 enrolled 7 charts
Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant
Phase 3 Terminated
240 enrolled
Blood Samples From Patients on a Clinical Trial to CINV During HSCT
Terminated
9 enrolled
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Phase 2 Terminated
6 enrolled 5 charts